Eli Lilly (LLY) EPS (Basic) (2009 - 2026)

Eli Lilly (LLY) has reported EPS (Basic) for 17 consecutive years, with $8.27 the latest figure, recorded in Q1 2026.

• EPS (Basic) for Q1 2026 came in at $8.27, up 169.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.26 (up 128.66% YoY), and the FY2025 annual result was $23.0, up 95.62% from the prior year.
• EPS (Basic) was $8.27 for Q1 2026 at Eli Lilly, up from $7.4 in the prior quarter.
• Over five years, EPS (Basic) peaked at $8.27 in Q1 2026 and troughed at -$0.06 in Q3 2023.
• Average EPS (Basic) over 5 years is $3.28, with a median of $2.43 recorded in 2023.
• Year-over-year, EPS (Basic) plunged 103.96% in 2023 and surged 1788.17% in 2024.
• Over 5 years, EPS (Basic) stood at $2.15 in 2022, then increased by 13.18% to $2.43 in 2023, then soared by 101.33% to $4.9 in 2024, then jumped by 51.08% to $7.4 in 2025, then rose by 11.77% to $8.27 in 2026.
• Per Business Quant data, the three most recent EPS (Basic) figures were $8.27 in Q1 2026, $7.4 in Q4 2025, and $6.22 in Q3 2025.